CONSENSUS PAPER   

Giornale Italiano di Dermatologia e Venereologia 2014 October;149(5):607-25

Copyright © 2014 EDIZIONI MINERVA MEDICA

language: English

Consensus on the use of cyclosporine in dermatological practice

Altomare G. ¹, Ayala F. ², Bardazzi F. ³, Bellia G. ⁴, Chimenti S. ⁵, Colombo D. ⁴, Flori M. L. ⁶, Girolomoni G. ⁷, Micali G. ⁸, Parodi A. ⁹, Peris K. ¹⁰, Vena G. A. ¹¹ ✉

¹ IRCCS Galeazzi, University of Milan, Milan, Italy; ² Department of Clinical Medicine and Surgery, Dermatology Clinic, University of Naples Federico II, Naples, Italy; ³ Dermatology Unit, Department of Specialist Diagnostic and Experimental Medicine, S. Orsola‑Malpighi Hospital, University of Bologna, Bologna, Italy; ⁴ Novartis Farma, Italy, Origgio, Varese, Italy; ⁵ Department of Dermatology, University of Rome “Tor Vergata”, Rome, Italy; ⁶ Dermatology Unit, Department of Clinical Medicine and Immunology, University of Siena, Siena, Italy; ⁷ Section of Dermatology, Department of Medicine, University of Verona, Verona; ⁸ Dermatology Clinic, University of Catania, A.O.U. Policlinico Vittorio Emanuele, Catania, Italy; ⁹ Section of Dermatology, IRCCS University Hospital San Martino‑IST Genoa, Italy; ¹⁰ Department of Dermatology, University of L’Aquila, L’Aquila, Italy; ¹¹ Private Practitioner, Bari and Barletta, Italy

Cyclosporine A (CsA) efficacy and safety have been proven in various dermatoses both in adults and in children even as long-term treatment. Over the last 25 years, Italian dermatologists have gathered relevant experience about CsA treatment for psoriasis and atopic dermatitis. This paper has been developed by an Italian Consensus Conference and it is aimed at providing recommendations based on real-world clinical experience in adult patients, consistent with efficacy and safety data arising from the scientific literature. The paper is mainly focused on the analysis of the optimal therapeutic schemes for psoriasis and atopic dermatitis, in terms of doses and treatment duration, according to individual characteristics and to the severity of the disease. Moreover, it overviews ideal management, taking into account pharmacological interactions, influence of comorbidities, and the most common adverse events related to CsA treatment.